A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia

Therapeutic Advances in Psychopharmacology

Volumn 2, Issue 3, 2012, Pages 115-125

  Wittkampf, Laura Christina ^a   Arends, Johannes ^b   Timmerman, Leo ^b   Lancel, Marike ^b  

^a GGZ Drenthe   (Netherlands)

^b Mental Health Services Drenthe   (Netherlands)

Author keywords

armodafinil; cognitive disturbances; fatigue; inactiveness; modafinil; schizophrenia

Indexed keywords

ARMODAFINIL; CLOZAPINE; MODAFINIL;

AGITATION; AUDITORY HALLUCINATION; COGNITION; DIARRHEA; DRUG TOLERABILITY; EPWORTH SLEEPINESS SCALE; EXECUTIVE FUNCTION; FATIGUE; FATIGUE SEVERITY SCALE; FOLLICULITIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEADACHE; HOSTILITY; HUMAN; INSOMNIA; MOTOR ACTIVITY; MUSCLE SPASM; NEGATIVE SYNDROME; PRIORITY JOURNAL; RECOGNITION; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; VERBAL MEMORY; VISUAL MEMORY; WEIGHT REDUCTION; WORKING MEMORY; XEROSTOMIA;

EID: 84998166025     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312441815     Document Type: Review

References (50)

1. Aggarwal A. Garg A. Jiloha R.C. (2009) Psychotic relapse in a patient with schizophrenia associated with modafinil therapy. Primary Psychiatry 16: 26–27.
2. Baldessarini R.J. Frankenburg F.R. (1991) Clozapine. A novel antipsychotic agent. N Engl J Med 324: 746–754.
3. Bobo W.V. Woodward N.D. Sim M.Y. Jayathilake K. Meltzer H.Y. (2011) The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial. Schizophr Res 130: 106–113.
4. Burke M. Sebastian C.S. (1993) Treatment of clozapine sedation. Am J Psychiatry 150: 1900–1901.
5. Curran C. Byrappa N. McBride A. (2004) Stimulant psychosis: systematic review. Br J Psychiatry 185: 196–204.
6. Darwish M. Kirby M. D’Andrea D.M. Yang R. Hellriegel E.T. Robertson P. Jr (2010) Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. Clin Ther 32: 2074–2087.
7. Dawson N. Thompson R.J. McVie A. Thomson D.M. Morris B.J. Pratt J.A. (2010) Modafinil reverses phencyclidine-Induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity. Schizophr Bull, DOI: 10.1093/schbul/sbq09010.1093/schbul/sbq090.
8. de Saint Hilaire Z. Orosco M. Rouch C. Blanc G. Nicolaidis S. (2001) Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 12: 3533–3537.
9. DeQuardo J.R. (2002) Modafinil-associated clozapine toxicity. Am J Psychiatry 159: 1243–1244.
10. DeQuardo J.R. (2004) Modafinil and antipsychotic induced sedation. J Clin Psychiatry 65: 278–279.
11. Eack S.M. Newhill C.E. (2007) Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull 33: 1225–1237.
12. Farrow T.F.D. Hunter M.D. Haque R. Spence S.A. (2006) Modafinil and unconstrained motor activity in schizophrenia. Br J Psychiatry 189: 461–462.
13. Ferraro L. Antonelli T. O’Connor W.T. Tanganelli S. Rambert F. Fuxe K. (1997) The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 8: 2883–2887.
14. Fischer B.A. Weiner E. (2008) Clozapine levels lowered by modafinil: a case report and brief review of modafinil in schizophrenia. Clin Schizophr Rel Psych 2: 88–90.
15. Freudenreich O. Henderson D.C. Macklin E.A. Evins A.E. Fan X. Cather C. et al. (2009) Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry 70: 1674–1680.
16. Gallopin T. Luppi P.H. Rambert F.A. Frydman A. Fort P. (2004) Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 27: 19–25.
17. Goetghebeur P. Dias R. (2009) Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat—a back translational study. Psychopharmacology 202: 287–293.
18. Henderson D.C. Louie P.M. Koul P. Namey L. Daley T.B. Nguyen D.D. (2005) Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient. Ann Clin Psychiatry 17: 95–97.
19. Henderson D.C. Freudenreich O. Borba C.P. Wang X. Copeland P.M. Macklin E. et al. (2011) Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr Res 130: 53–56.
20. Hermant J.F. Rambert F.A. Duteil J. (1991) Awakening properties of modafinil: effect on nocturnal activity in monkeys (Macaca mulatta) after acute and repeated administration. Psychopharmacology 103: 28–32.
21. Hill S.K. Reilly J.L. Harris M.S. Khine T. Sweeney J.A. (2008) Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia. Schizophr Bull 34: 494–506.
22. Hunter M.D. Ganesan V. Wilkinson I.D. Spence S.A. (2006) Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry 163: 2184–2186.
23. Ishizuka T. Sakamoto Y. Sakurai T. Yamatodani A. (2003) Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 339: 143–146.
24. Kane J.M. D’Souza D.C. Patkar A.A. Youakim J.M. Tiller J.M. Yang R. et al. (2010) Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J Clin Psychiatry 71: 1475–1481.
25. Leucht S. Corves C. Arbter D. Engel R.R. Li C. Davis J.M. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31–41.
26. Madras B.K. Xie Z. Lin Z. Jassen A. Panas H. Lynch L. et al. (2006) Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319: 561–569.
27. Makela E.H. Miller K. Cutlip W.D. (2003) Three case reports of modafinil use in treating sedation induced by antipsychotic medications. J Clin Psychiatry 64: 485–486.
28. McFadden S.L. Zulas A.L. Morgan R.E. (2010) Age-dependent effects of modafinil on acoustic startle and prepulse inhibition in rats. Behav Brain Res 208: 118–123.
29. Meyer J.M. Davis V.G. Goff D.C. McEvoy J.P. Nasrallah H.A. Davis S.M. et al. (2008) Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 101: 273–286.
30. Minzenberg M.J. Carter C.S. (2008) Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33: 1477–1502.
31. Mohamed S. Rosenheck R. Swartz M. Stroup S. Lieberman J.A. Keefe R.S. (2008) Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 165: 978–987.
32. Narendan R. Young C.M. Valenti A.M. Nickolova M.K. Pristach C.A. (2002) Is psychosis exacerbated by modafinil? Arch Gen Psychiatry 59: 292–293.
33. Ozer S. Demir B. (2010) Hypomania in a schizophrenic patient treated with modafinil for clozapine-induced sedation. Noropsikiyatri Arsivi 47: 171–173.
34. Pedersen C.S. Goetghebeur P. Dias R. (2009) Chronic infusion of PCP via osmotic mini-pumps: A new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance. J Neurosci Methods 185: 66–69.
35. Pierre J.M. Peloian J.H. Wirshing D.A. Wirshing W.C. Marder S.R. (2007) A randomized, double-blind, placebo-controlled trial of Modafinil for negative symptoms in schizophrenia. J Clin Psychiatry 68: 705–710.
36. Pirmohamed M. Williams D. Madden S. Templeton E. Park B.K. (1995) Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 272: 984–990.
37. Redrobe J.P. Bull S. Plath N. (2010) Translational aspects of the novel object recognition task in rats abstinent following subchronic treatment with phencyclidine (PCP): effects of modafinil and relevance to cognitive deficits in schizophrenia. Nihon Yakurigaku Zasshi 136: 133–136.
38. Robertson P. Decory H.H. Madan A. Parkinson A. (2000) In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 28: 664–671.
39. Rosenthal M.H. Bryant S.L. (2004) Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin Neuropharmacol 27: 38–43.
40. Ross C.A. Margolis R.L. Reading S.A. Pletnikov M. Coyle J.T. (2006) Neurobiology of schizophrenia. Neuron 52: 139–153.
41. Salimi K. Jarskog L.F. Lieberman J.A. (2009) Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs 23: 837–855.
42. Scoriels L. Barnett J.H. Murray G.K. Cherukuru S. Fielding M. Chen F. et al. (2011) Effects of modafinil on emotional processing in first episode psychosis. Biol Psychiatry 69: 457–464.
43. Sepehry A.A. Potvin S. Elie R. Stip E. (2007) Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry 68: 604–610.
44. Sevy S. Rosenthal M.H. Alvir J. Meyer S. Visweswaraiah H. Gunduz-Bruce H. et al. (2005) Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 66: 839–843.
45. Spence S.A. Green R.D. Wilkinson I.D. Hunter M.D. (2005) Modafinil modulates anterior cingulate function in chronic schizophrenia. Br J Psychiatry 187: 55–61.
46. Tuominen H.J. Tiihonen J. Wahlbeck K. (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72: 225–234.
47. Turner D.C. Clark L. Pomarol-Clotet E. McKenna P. Robbins T.W. Sahakian B.J. (2004) Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29: 1363–1373.
48. Valentino R.M. Foldvary-Schaefer N. (2007) Modafinil in the treatment of excessive daytime sleepiness. Cleve Clin J Med 74: 561–566, 568–571.
49. Wisor J.P. Nishino S. Sora I. Uhl G.H. Mignot E. Edgar D.M. (2001) Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21: 1787–1794.
50. Young J.W. Kooistra K. Geyer M.A. (2011) Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil. Neuropsychopharmacology 36: 1358–1396.